N-1 substituted pyrimidin-4-ones: novel, orally active inhibitors of lipoprotein-associated phospholipase A2
摘要:
From two related series of 2-(alkylthio)-pyrimidones, a novel series of 1-((amidolinked)-alkyl)-pyrimidones has been designed as nanomolar inhibitors of human lipoprotein-associated phopholipase A(2). These compounds show greatly enhanced activity in isolated plasma. Selected derivatives such as compounds 51 and 52 are orally active with a good duration of action. (C) 2000 Elsevier Science Ltd. All rights reserved.
N-1 substituted pyrimidin-4-ones: novel, orally active inhibitors of lipoprotein-associated phospholipase A2
摘要:
From two related series of 2-(alkylthio)-pyrimidones, a novel series of 1-((amidolinked)-alkyl)-pyrimidones has been designed as nanomolar inhibitors of human lipoprotein-associated phopholipase A(2). These compounds show greatly enhanced activity in isolated plasma. Selected derivatives such as compounds 51 and 52 are orally active with a good duration of action. (C) 2000 Elsevier Science Ltd. All rights reserved.
[EN] PYRIMIDINONE COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM<br/>[FR] COMPOSES DE PYRIMIDINONE ET COMPOSITIONS PHARMACEUTIQUES LES RENFERMANT
申请人:SMITHKLINE BEECHAM PLC
公开号:WO1999024420A1
公开(公告)日:1999-05-20
(EN) A group of novel pyrimidone compounds are inhibitors of the enzyme LDL PLA2 and therefore of use in treating atherosclerosis.(FR) L'invention concerne un groupe de nouveaux composés de pyrimidinone qui sont des inhibiteurs de l'enzyme LDL PLA2 et qui s'utilisent donc pour le traitement de l'athérosclérose.